AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company with the primary focus to discover, develop and commercialize prescription medicines for six important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory & Inflammation.

AstraZeneca also works with others to combine complementary skills and strengthen the platform for success in meeting a common goal: improved healthcare. The company invests over $4 billion in R&D each year. About 11,300 work under its R&D organisation, with 14 principal R&D centres in eight countries, and 9,600 employees work at Supply and Manufacturing sites in 16 countries.

AstraZeneca employs over 57,200 people (46% in Europe, 31% in the Americas and 23% in Asia-Pacific) and is active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.

Medicines

• Cardiovascular
• Gastrointestinal
• Infection
• Neuroscience
• Oncology
• Respiratory

Mission

Their mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for their stakeholders and society.

They believe that the most value-creating strategy for AstraZeneca is to be a focused, integrated, innovation-driven, global, prescription-based biopharmaceutical business:

• biopharmaceutical in that they will develop both chemical (small molecule) and biological (large molecule) medicines
• focused in that they will continue to be selective about those areas of the pharmaceutical industry in which they choose to compete, targeting those product categories where medical innovation or brand equity will continue to enable them to make acceptable levels of return on their investments
• integrated in that they believe the best way to capture value within this industry is to span the full value chain of discovery, development and commercialisation, while continuing to work with partners and outsourcing to capture operational efficiencies
• innovation-driven in that they believe their technology base will continue to deliver innovative products that will benefit patients and for which payers will pay
• global in that they believe they have the ability to meet healthcare needs in both established and emerging markets efficiently and effectively.

They believe that there continue to be opportunities to create value for those who invest in pharmaceutical innovation, and that AstraZeneca has the skills and capabilities to take advantage of these opportunities and turn them into long-term value through the research, development and marketing of medicines. For them, this is the core of their commitment to their stakeholders and society. Successful pharmaceutical innovation, delivered responsibly, brings benefits to patients, creates sustainable value for shareholders and contributes to the economic and social welfare of the communities they serve.